Those patches were reduced in the nicotinamide group by 11 % at three months, and by 20 % at nine a few months of treatment. Nevertheless, those benefits quickly disappeared through the study’s follow-up period. ‘When people halted taking their tablets after 12 months, the benefit was no longer seen,’ Damian said. ‘In other words, you need to continue acquiring the tablets to allow them to be effective.’ Nicotinamide did not appear to cause any longer adverse events compared to the placebo, the researchers added. Damian said that nicotinamide is very different from a more commonly known type of B3 called niacin. Individuals who take high dosages of niacin can have problems with headaches, flushed skin and low blood circulation pressure. ‘These side effects are not and were not seen with nicotinamide,’ she stated.‘Merck’s actions were correct and didn’t, in any way, demand this award as described by New Jersey laws,’ stated Chuck Harrell, spokesman for Merck’s legal group. He said the company’s appeal would concentrate on evidence and testimony condition Superior Court Judge Carol Higbee barred from the trial, including limitations she set on expert witnesses. ‘The evidence was clear that people offered the U.S. Food and Medication Administration with the given information about Vioxx that people were required to provide. And under NJ law, that means punitive damages shouldn’t have already been awarded,’ Harrell said.